LOUISVILLE, Ky. and HOUSTON, Jan. 8, 2018 /PRNewswire/ — NX Prenatal Inc., a US based molecular diagnostics company utilizing its proprietary NeXosome® technology for early warning of adverse pregnancy outcomes, announced today that data from its ongoing validation studies will be…












